Peptide Knowledge Base · Longevity
FOXO4-DRI: what it is, what the evidence says, and its real status
A senolytic peptide designed to clear senescent ('zombie') cells by triggering their apoptosis, preclinical only.
Short version: the senolytic frontier, a peptide built to make worn-out cells self-destruct. Striking in mice, untested in people. A watch item, education only.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: Research-only · Education only.
Not offered, frontier research, education only. FOXO4-DRI is a preclinical senolytic peptide with no human data and an apoptosis-inducing mechanism. It is not FDA-approved and not available; we track it as a watch item.
How does FOXO4-DRI work?
A peptide that disrupts the FOXO4–p53 interaction in senescent cells, selectively pushing them into apoptosis.
What it does — and what it does not do
What it does: Cleared senescent cells and improved markers of aging in mouse studies.
What it does not do: It has no human data, is not approved, and is not available, the mechanism is powerful and unproven in people.
How honest is the evidence?
Evidence grade D — preclinical only; no human data. Read our grading methodology for what each grade means.
What we still don't know: No human safety or efficacy data; off-target apoptosis risk is uncharacterized.
WADA status: Not prohibited.
How it is taken
No established human clinical dosing; preclinical.
Who should not take it
Apoptosis-inducing mechanism; not characterized for human safety.
Sources
Baar et al., FOXO4-DRI senolytic (Cell 2017)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.